Free Trial
→ Louis Navellier: My #1 AI stock for 2026 (name & ticker inside) (From InvestorPlace) (Ad)tc pixel
NASDAQ:VERA

Vera Therapeutics Q3 2026 Earnings Date & Estimates

Vera Therapeutics logo
$29.73 -0.52 (-1.72%)
Closing price 10/8/2026 04:00 PM Eastern
Extended Trading
$29.67 -0.06 (-0.19%)
As of 05:20 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Vera Therapeutics is expected to report Q3 2026 earnings on Wednesday, November 4, 2026, before market opens. The conference call is scheduled for November 5, 2026 at 4:00 PM ET.

Research:ProfileEarnings HistoryForecast

Upcoming Earnings Announcement

Quarter
Q3 2026
Announcement Date
Time
Before Market Opens
Conference Call Date
Conference Call
4:00 PM ET
Google Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab)

What Analysts Expect from Vera Therapeutics in Q3 2026

Vera Therapeutics is expected to post earnings of -$1.61 per share on revenue of $4.28 million. In the same quarter a year earlier Vera Therapeutics reported -$1.26 per share. Vera Therapeutics last reported on August 10, 2026, posting -$1.52 per share and beating the -$1.58 consensus estimate. Vera Therapeutics has beaten the consensus EPS estimate in 2 of its last 8 quarters.

Consensus Estimates

Consensus EPS
-$1.61
Expected Revenue
$4.28 million
Prior-Year EPS
-$1.26

Recent Track Record

Last Reported
Q2 2026
Last Quarter EPS
-$1.52 (Beat by +$0.06)
EPS Beat Rate
2 of last 8 quarters

Prepare for the Q3 2026 Call

Vera Therapeutics Q3 2026 Earnings FAQ

Vera Therapeutics (NASDAQ:VERA) is estimated to report Q3 2026 earnings on Wednesday, November 4, 2026, before market opens. This date is estimated from past reporting schedules and may change once the company confirms it.

Vera Therapeutics' Q3 2026 earnings conference call is scheduled for Thursday, November 5, 2026 at 4:00 PM ET. MarketBeat streams the conference call audio and posts the transcript as soon as possible on the earnings announcement date.

Analysts expect Vera Therapeutics to post earnings of -$1.61 per share for Q3 2026.

The consensus revenue estimate for Vera Therapeutics is $4.28 million for Q3 2026.

Vera Therapeutics Earnings Headlines

Vera Therapeutics, Inc. (NASDAQ:VERA) Stock Has Consensus Target Price of $80.15
October 8 at 2:28 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31097954
Vera Therapeutics Announces ORIGIN 3 Final Efficacy Analysis of TRUTAKNA in IgA Nephropathy Will be A Featured Late-breaking Oral Presentation at the Opening Plenary Session of ...
October 5, 2026  |  marketscreener.comM
Ready to give options a try? Your first trade (Ticker included) -INSIDE
Tired of trying tactic after tactic when it comes to options trades... only to be met with market noise and stinging losses? Dave Aquino is giving away the exact 11-hour options strategy he uses in volatile markets. You get the plain English blueprint behind the strategy and the very same "rinse and repeat" ticker he's traded nearly 900 times with a 95.3% success rate. It's so simple to understand, you could trade it tomorrow.tc pixel
 |  Base Camp Trading (Ad)
Vera Therapeutics Announces Origin 3 Final Efficacy Analysis of TRUTAKNA in Iga Nephropathy Will Be A Featured Late-Breaking Oral Presentation At Asn Kidney Week 2026
October 3, 2026  |  marketscreener.comM
Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
October 2, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/10/02/3374017/0/en/vera-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4.html
Vera Therapeutics Announces ORIGIN 3 Final Efficacy Analysis of TRUTAKNA™ (atacicept-vymj) in IgA Nephropathy Will be A Featured Late-breaking Oral Presentation at the ...
October 2, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/vera-therapeutics-announces-origin-3-132400137.html
See More Vera Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Vera Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Vera Therapeutics and other key companies, straight to your email.

About Vera Therapeutics

Vera Therapeutics (NASDAQ:VERA) is a clinical-stage biotechnology company focused on developing treatments for immune-mediated diseases. The company’s lead product candidate is atacicept, an investigational fusion protein designed to inhibit two immune signaling molecules, B-cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), which contribute to the survival and activity of antibody-producing B cells.

Vera is primarily studying atacicept as a potential treatment for immunoglobulin A nephropathy (IgA nephropathy), a chronic kidney disorder caused by the buildup of IgA immune complexes. The company has also evaluated the therapy in other autoimmune conditions, including systemic lupus erythematosus and multiple sclerosis. Atacicept remains an investigational product and has not been approved for commercial use.

Founded in 2016 and headquartered in South San Francisco, California, Vera conducts its research and clinical development activities through international studies involving patients and medical centers in multiple regions. The company was founded by Marshall Fordyce, who has served as its chief executive officer. Vera Therapeutics is listed on the Nasdaq Stock Market under the symbol VERA.

View Vera Therapeutics Profile
Earnings Tools